Anuradha Krishnamurthy, MBBS

Anuradha Krishnamurthy practices at Roswell Park Cancer Institute in Los Angeles, California.

Anuradha Krishnamurthy's NPI, 1710333943, was assigned on May 6, 2016. Anuradha Krishnamurthy graduated from University of Sydney Faculty of Medicine in 2010. Anuradha Krishnamurthy holds Pennsylvania license MD464592.

Anuradha Krishnamurthy's primary practice is Roswell Park Cancer Institute, at 344 S Hauser Blvd, Los Angeles, CA 90036 in Los Angeles County. The practice phone is (716) 845-2300.

Anuradha Krishnamurthy's primary practice is Roswell Park Cancer Institute in Los Angeles, California. Anuradha Krishnamurthy is also affiliated with Roswell Park Comprehensive Cancer Center. The medical group on file is University of Pittsburgh Physicians, Department of Radiology. Dmand AI also links Anuradha Krishnamurthy to 1 more medical group, named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Anuradha Krishnamurthy practices. Vendor and product names are available with a free account.

Medical oncology is Anuradha Krishnamurthy's primary specialty in the NPI Registry, under taxonomy code 207RX0202X. Anuradha Krishnamurthy is licensed in Pennsylvania.

CMS data shows 56 Medicare services from Anuradha Krishnamurthy across 1 procedure code in 2024, all of them office visits, for 33 Medicare patients. Medicare paid $5,969 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 33 Medicare patients who saw Anuradha Krishnamurthy in 2024. The largest group is 65 to 74, with 16 patients. 75% of them have cancer, and 75% have high cholesterol. Their average risk score is 2.31, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Anuradha Krishnamurthy's median patient age at 69, with 48% women.

In 2024, Anuradha Krishnamurthy wrote 72 Medicare Part D claims for 33 patients. 79% of them were for generic drugs. CMS names the drug for 11 of them, across 1 drug with 11 or more claims each, at $7,844 in total drug cost. In 2022, CMS named 46 claims across 4 drugs.

Anuradha Krishnamurthy accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Anuradha Krishnamurthy as offering telehealth.

Dmand AI links 12 papers to Anuradha Krishnamurthy, published from 2017 to 2025. 2022 was the busiest year, with 3. The most frequent topics are Antineoplastic Combined Chemotherapy Protocols, Antineoplastic Agents and Colorectal Neoplasms. Anuradha Krishnamurthy's most frequent co-authors are Wells A. Messersmith, MD, James P. Ohr, DO and Amita Patnaik, MD.

Dmand AI links Anuradha Krishnamurthy to 10 clinical trials, 4 of them phase 2 studies. 8 are still active or recruiting. Conditions studied include Carcinoma, Neuroendocrine, Colorectal Neoplasms and Small Cell Lung Carcinoma. National Cancer Institute (NCI) sponsors the most, 7.

CMS Open Payments shows 4 general payments to Anuradha Krishnamurthy from 3 drug and device companies from 2022 to 2024. Food and beverage make up the largest share, 100% of the total. Ipsen Biopharmaceuticals, Inc paid the most, $151.

Anuradha Krishnamurthy graduated from University of Sydney Faculty of Medicine in 2010.